The site may be slightly tender for a short while afterward, but most people find it very manageable and are back to their day right away
Cell 75 , 442456.e444 (2019)
Labrune P, Myara A, Hadchouel M, Ronchi F, Bernard O, Trivin F et al
doi: 10.1056/NEJMcp1710945 89 SinghNBabyDRajguruJPPatilPBThakkannavarSSPujariVB
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls